Last deal

$23M

Amount

Series D

Stage

31.03.2005

Date

3

all rounds

$43M

Total amount

General

About Company
Confluent Surgical develops biomaterials for surgical sealing and adhesion prevention.

Industry

Sector :

Subsector :

founded date

01.01.1998

Number of employees

Company Type

For Profit

Last funding type

Series D

IPO status

Private

Description

Founded in 1998 and headquartered in Waltham, Massachusetts, Confluent Surgical develops a range of biomaterial products, including sealants, adhesion barriers, and hemostatic agents, to address complications during and after surgery. Their flagship product, DuraSeal Dural Sealant, is used for watertight closure during cranial surgeries. Acquired by US Surgical in 2006, Confluent Surgical focuses on developing products based on their proprietary technology of in-situ polymerized hydrogels and associated delivery systems.